5-(2-吡啶基)噻吩-2-羧胺 | 175202-40-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-(2-吡啶基)噻吩-2-羧胺
• 中文别名: 2-[2-硝基-4-(1,2,3,4-四氢异喹啉-2-基磺酰基)苯基]-1,2,3,4-四氢异喹啉
• 英文名称: 5-(2-Pyridyl)thiophene-2-carboxamide
• 英文别名: 5-pyridin-2-ylthiophene-2-carboxamide
• CAS: 175202-40-1
• 化学式: C₁₀H₈N₂OS
• mdl: MFCD00085163
• 分子量: 204.25
• InChiKey: BPSZHKPVINNIBN-UHFFFAOYSA-N

物化性质

• 熔点：
  194-197°C
• 沸点：
  393.5±32.0 °C(Predicted)
• 密度：
  1.308±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2934999090

文献信息

• New Piperazine Compound and Use Thereof as a HCV Polymerase Inhibitor
  申请人：Abe Hiroyuki

  公开号：US20080081818A1

  公开（公告）日：2008-04-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的化合物，其中每个符号如规范中定义，或其药学上可接受的盐，或其溶剂化合物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，并且可用作预防或治疗丙型肝炎的药剂。
• Benzimidazoles
  申请人：Edwards L. Michael

  公开号：US20060014756A1

  公开（公告）日：2006-01-19

  The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

  本发明涉及一般式（Ix）的生理活性化合物及含有这种化合物的组合物，以及它们的前药、药学上可接受的盐和溶剂化物，还涉及在式（Ix）范围内的新化合物和它们的制备方法。这种化合物和组合物具有有价值的药物性质，特别是抑制激酶的能力。
• 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors
  申请人：Vicker Nigel

  公开号：US20090042929A1

  公开（公告）日：2009-02-12

  There is provided a compound having Formula (I) R 1 -Z-R 2 wherein R 1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycloalkyl groups Z is a linker which is or comprises a carbonyl group or a isostere of a carbonyl group R 2 is selected from optionally substituted aromatic rings and optionally substituted heterocyclic rings wherein (a) R 2 is a 2-substituted thiophene group, and/or (b) Z is a group of the formula —C(═O)—CR 3 R 4 —X—(CR 5 R 6 )n-, wherein X is selected from NR 7 , S, O, S═O, and S(═O) 2 , wherein n is 0 or 1 and/or (c) R 1 is an adamantyl group and Z is or comprises an amide group, and/or (d) R 1 is an adamantyl group and Z is or comprises a group of the formula —(CR 8 R 9 )p-NR 10 —S(═O) 2 —(CR 11 R 12 )q-, wherein p is 0 or 1 and q is 0 or 1 and/or (e) R 1 is an adamantyl group and Z is or comprises a group of the formula —(CR 13 R 14 )V—Y—(CR 15 R 16 )W— where Y is a heteroaryl group in which a bond in the heteroaryl ring is a isostere of a carbonyl group, wherein v is o or 1 and w is 0 or 1; wherein each of R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 , are independently selected from H, hydrocarbyl and halogen, wherein each of R 7 and R 10 are independently selected from H and hydrocarbyl.

  提供一种化合物，其化学式为(I) R1-Z-R2，其中R1是选自可选取代的融合多环基团、取代的烷基基团、支链烷基基团和可选取代的环烷基基团的基团；Z是一个连接基团，可以是或包含一个羰基基团或一个羰基基团的同分异构体；R2是选自可选取代的芳香环和可选取代的杂环；其中(a) R2是2-取代噻吩基团，和/或(b) Z是一个化学式为—C(═O)—CR3R4—X—(CR5R6)n-的基团，其中X选自NR7、S、O、S═O和S(═O)2，n为0或1，和/或(c) R1是一个金刚烷基团，Z是或包含一个酰胺基团，和/或(d) R1是一个金刚烷基团，Z是或包含一个化学式为—(CR8R9)p-NR10—S(═O)2—(CR11R12)q-的基团，其中p为0或1，q为0或1，和/或(e) R1是一个金刚烷基团，Z是或包含一个化学式为—(CR13R14)V—Y—(CR15R16)W—的基团，其中Y是一个杂环基团，在杂环环中的一个键是羰基基团的同分异构体，v为0或1，w为0或1；其中R3、R4、R5、R6、R8、R9、R11、R12、R13、R14、R15和R16各自独立地选自H、烃基和卤素，R7和R10各自独立地选自H和烃基。
• NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR
  申请人：Abe Hiroyuki

  公开号：US20120107273A1

  公开（公告）日：2012-05-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由下式[I]表示的化合物，其中每个符号如规范所定义，或其药学上可接受的盐，或其溶剂化物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性表现出抗HCV活性，可作为预防或治疗丙型肝炎的药剂。
• Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
  申请人：Schmitz Franz Ulrich

  公开号：US20120121540A1

  公开（公告）日：2012-05-17

  Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).

  提供了某些化学实体、制药组合物和治疗方法，用于治疗黄病毒科的成员，例如丙型肝炎病毒（丙肝或HCV）。